palbociclib

10/01/2020 - "We aimed to evaluate the efficacy of palbociclib, an oral inhibitor of CDK4/6 with proven efficacy in breast cancer, in patients with AO. "
01/01/2019 - "More specifically, palbociclib was associated with significant improvement of PFS (HR: 0.518, 95% CI: 0.444-0.604) in the treatment of ER-positive and HER2-negative breast cancer. "
01/01/2020 - "Poor efficacy of palbociclib in second-line treatment of metastatic lobular breast cancer in a case series: Use before or never more?"
02/01/2024 - "Palbociclib: Safe and Effective in an 85-Year-Old Female with Metastatic Bilateral Breast Cancer."
01/01/2016 - "Results of pivotal phase III trials investigating palbociclib in patients with advanced-stage oestrogen receptor (ER)-positive breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile. "

09/13/2022 - "After 3 weeks of treatment, the combination produced a significant reduction in number and size of tumor nodules in comparison with palbociclib or miR-199a-3p mimics used as single agents. "
11/16/2023 - "We found that continuous dosing of palbociclib is more effective for lowering overall tumor burden than the standard, pulsed-dose palbociclib treatment. "
05/01/2019 - "Consistently, palbociclib was effective in controlling tumor growth in mice. "
01/01/2019 - "We performed this meta-analysis to estimate the safety and efficacy of palbociclib in cancer patients from clinical trials. "
01/01/2024 - "Thus, although accumulating evidence suggests that anti-cancer effects of CDK4/6 inhibitors also depend on the promotion of antitumor immune responses, assessing cell cycle arrest and progression in cells treated with palbociclib remains a key approach for investigating the efficacy of CDK4/6 inhibitors. "

01/01/2017 - "Our results warrant a clinical trial to further evaluate the efficacy of PD-0332991 in ESCC patients, even those with metastasis."
03/22/2023 - "These studies shed light on how stromal senescence induced by palbociclib affects lung metastasis, and they describe palbociclib-induced gene expression changes in the normal lung and endothelial cell models that correlate with changes in the tumor microenvironment in the lung metastatic niche."
10/01/2021 - "Compared with those in the IRIS study, Chinese patients receiving palbociclib-based treatment were younger, and they had fewer bone-only metastases and more visceral and liver metastases. "
02/01/2024 - "Subgroup analysis found favorable g values in visceral metastases treated with palbociclib. "
03/22/2023 - "Notably, lung metastases from palbociclib-pretreated mice revealed senescent endothelial cells. "

01/01/2020 - "TKa was assayed in plasma obtained at baseline (T0), after one cycle (T1), and at disease progression on palbociclib (T2) in patients enrolled in the "To Reverse ENDocrine Resistance" (TREnd) trial (n = 46). "
04/15/2024 - "PFS1 and OS1 were calculated from palbociclib administration to disease progression/death and death from any cause, respectively. "
01/01/2023 - "In ESR1-MUT MBC with disease progression on ET plus palbociclib, the median PFS was 7.0 months for CDKi-R(-) (n = 17) versus 3.5 months for CDKi-R(+) (n = 11), with a hazard ratio of 2.8 (P = .03). "
01/01/2021 - "Blood samples were collected before starting palbociclib treatment (timepoint T0), after the first cycle of treatment (timepoint T1), and at disease progression (timepoint T2). "
01/01/2020 - "Palbociclib 125 mg was orally administered once daily for 21 of 28 days until disease progression or unacceptable toxicity. "

12/01/2022 - "Thus, innovative agents to augment the efficacy of palbociclib in HPVneg HNSCC would be welcomed. "
09/01/2021 - "In this study, we investigated the inhibitory activity of palbociclib against oral squamous cell carcinoma (OSCC) cells and explored the mechanism of inhibition. "
03/27/2024 - "Palbociclib remarkably inhibited migration, invasion and the expression MMP-9 in HNSCC cells. "
12/01/2022 - "Palbociclib displayed limited efficacy in HPVneg HNSCC as monotherapy. "
09/01/2021 - "Palbociclib was found to have anti-oral squamous cell carcinoma activity and to simultaneously induce DNA damage and inhibit its repair, and to accelerated cellular senescence and apoptosis."